Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hajar Owji

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Expert Opinion on Biological Therapy|August 7, 2019
Selected application of peptide molecules as pharmaceutical agents and in cosmeceuticalsManica Negahdaripour, Hajar Owji, Mahboobeh Eslami, et al.
Antibodies (Basel, Switzerland)|September 23, 2024
A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells without Mediating FratricideGe Yang, Shahryar Khoshtinat Nikkhoi, Hajar Owji, et al.
Immunologic Research|August 26, 2023
A high affinity and specificity anti-HER2 single-domain antibody (VHH) that targets trastuzumab's epitope with versatile biochemical, biological, and medical applicationsShahryar Khoshtinat Nikkhoi, Hediyeh Heydarzadeh, Venu Gopal Vandavasi, et al.
Journal for Immunotherapy of Cancer|March 15, 2024
Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG miceShahryar Khoshtinat Nikkhoi, Ge Yang, Hajar Owji, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Expert Opinion on Biological Therapy|August 7, 2019
Selected application of peptide molecules as pharmaceutical agents and in cosmeceuticalsManica Negahdaripour, Hajar Owji, Mahboobeh Eslami, et al.
Antibodies (Basel, Switzerland)|September 23, 2024
A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells without Mediating FratricideGe Yang, Shahryar Khoshtinat Nikkhoi, Hajar Owji, et al.
Immunologic Research|August 26, 2023
A high affinity and specificity anti-HER2 single-domain antibody (VHH) that targets trastuzumab's epitope with versatile biochemical, biological, and medical applicationsShahryar Khoshtinat Nikkhoi, Hediyeh Heydarzadeh, Venu Gopal Vandavasi, et al.
Journal for Immunotherapy of Cancer|March 15, 2024
Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG miceShahryar Khoshtinat Nikkhoi, Ge Yang, Hajar Owji, et al.
Pageof 2